Genetic research has shown that mutations that modify the protein-coding sequence of ATP1A3, the gene encoding the α3 subunit of Na(+)/K(+)-ATPase, cause both rapid-onset dystonia parkinsonism and alternating hemiplegia of childhood. These discoveries link two clinically distinct neurological diseases to the same gene, however, ATP1A3 mutations are, with one exception, diseasespecific. Although the exact mechanism of how these mutations lead to disease is still unknown, much knowledge has been gained about functional consequences of ATP1A3 mutations using a range of in-vitro and animal model systems, and the role of Na(+)/K(+)-ATPases in the brain. Researchers and clinicians are attempting to further characterise neurological manifestations associated with mutations in ATP1A3, and to build on the existing molecular knowledge to understand how specific mutations can lead to different diseases. Genetic research has shown that mutations that modify the protein-coding sequence of ATP1A3, the gene encoding the α 3 subunit of Na + /K + -ATPase, cause both rapid-onset dystonia parkinsonism and alternating hemiplegia of childhood. These discoveries link two clinically distinct neurological diseases to the same gene, however, ATP1A3 mutations are, with one exception, disease-specifi c. Although the exact mechanism of how these mutations lead to disease is still unknown, much knowledge has been gained about functional consequences of ATP1A3 mutations using a range of invitro and animal model systems, and the role of Na + /K + -ATPases in the brain. Researchers and clinicians are attempting to further characterise neurological manifestations associated with mutations in ATP1A3, and to build on the existing molecular knowledge to understand how specifi c mutations can lead to diff erent diseases.
Introduction
The introduction of next-generation sequencing technology, which allows nearly complete assessment of human exomes and genomes, has signifi cantly boosted gene discovery. 1 These gene discoveries have advanced our knowledge of disease-specifi c pathophysiology, and have enabled genetic connections to be made between diseases. An example is the recent identifi cation of mutations in ATP1A3, a gene previously associated with rapid-onset dystonia parkinsonism (RDP), in alternating hemiplegia of childhood (AHC). This genetic connection between diseases off ers unique research opportunities to explore how genetics governs specifi c clinical phenotypes, and to study the underlying pathophysiology.
Here, we review current knowledge of the roles of ATP1A3 in the brain, as well as the phenotypes associated with mutations in the gene. Finally, we discuss additional research needed to further characterise the full phenotypic spectrum associated with mutations in ATP1A3 and the associated changes in protein function, to establish possible strategies for the development of new treatments for AHC, RDP, and related disorders. + ions moving inwards. The resulting ionic gradients establish membrane potentials that generate electrical impulses and move neurotransmitters and Ca 2+ across the plasma membrane. Na + /K + -ATPases consist of catalytic α, β, and regulatory γ subunits (fi gure 1). The main role of the α subunit is to bind and transport Na + and K + . There are four α subunits, all encoded by diff erent genes. The α 3 subunit, encoded by ATP1A3, is the predominant α subunit expressed in neurons, [2] [3] [4] although many neurons also express α 1 . The α 3 subunit diff ers from α 1 in that it has a comparatively low affi nity for Na + and K + , 5, 6 which enables rapid normalisation of ion gradients after intense neuronal fi ring. Changes in the activity of Na + /K + -ATPases in neurons (predominantly expressing α 3 ) have physiological consequences. For example, inhibition of Na + /K + -ATPases in the thalamus converts neuronal bursting responses to single spike discharges. 7 In the hippocampus, reduction of the activity of Na + /K + -ATPase causes interictal epileptiform bursting activity. 8 Furthermore, localisation of α 3 in dendritic spines has been shown to play a part in controlling the size and speed of the small depolarisations caused by fl uctuations of intracellular Na + that occur during activation of iongating neurotransmitter receptors. These fl uctuations, known as transients, are summated in dendrites and are the basis of synaptic integration. [9] [10] [11] In addition to its primary function in ion transport, subunits of Na + /K + -ATPases have been shown to interact with proteins that assist in localisation of enzymes to the cell membrane, modulate the PI3K, PLCγ, and MAPK signal transduction cascades, and regulate the activity of other transporters and receptors. 12 The protein-protein interactions specifi c to the α 3 subunit are not fully characterised, but, as an example, the α 3 isoform has been shown in rat neurons to bind specifi cally to PSD95, a scaff olding protein that organises proteins at the synapse.
Roles of Na
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ATP1A3 mutations and neurological disorders
In 1999, two large families were identifi ed with several members presenting with RDP. 13, 14 Linkage analyses identifi ed the 19q13 locus as the region most likely to harbour mutations associated with disease; 15 a fi nding that was confi rmed in additional families with RDP. 16, 17 RDP in all these families was inherited as an autosomal dominant trait with incomplete penetrance. Using a positional cloning approach, investigators identifi ed six diff erent heterozygous missense mutations in ATP1A3 that co-segregated with the disease phenotype. 18 Since the initial discovery, 11 mutations (nine missense mutations, a 3-bp in-frame deletion, and a 3-bp in-frame insertion; fi gure 2; table 1 [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] ) have been reported in 20 patients with RDP, 12 of whom had a positive family history of the disease. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] 35 Three mutations, one found only in sporadic RDP cases and two found in both sporadic and familial RDP cases, are recurrent, probably because they are located at hypermutable methylated CpG-dinucleotides in ATP1A3 (table 1) . 36 For the Exome Variant server see http://evs.gs.washington.
edu/EVS/ In 2012, two independent studies, one by an international consortium 31 and one by German researchers, 32 identifi ed de-novo mutations in ATP1A3 as the cause of AHC. In both studies next-generation sequencing was used to screen the protein-coding portion of the genome of patients with sporadic AHC to look for disease-causing mutations that were absent in their unaff ected parents. This approach identifi ed a de-novo ATP1A3 mutation in each of the ten initial patients screened in the two studies combined, which defi nitively establishes ATP1A3 as the fi rst AHC gene. 31, 32 This fi nding was replicated in an independent Japanese study, 33 which found ATP1A3 mutations in eight of ten patients with AHC. The German study identifi ed mutations in all 24 German patients with AHC. 32 Notably, the international study reported ATP1A3 mutations in 82 (78%) of 105 patients with AHC, 31 which suggests that some ATP1A3 mutations might have been missed, that other AHC genes might exist, or that the diagnosis might not always be accurate. 27 diff erent ATP1A3 mutations have been reported in patients with AHC (fi gure 2, table 1). Ten mutations have been identifi ed in more than one individual, with one mutation (Asp801Asn) explaining more than 40% of AHC cases with an ATP1A3 mutation (table 1) .
When we consider the location in the ATP1A3 protein sequence of mutations that cause RDP or AHC, an interesting diff erence emerges. Whereas RDP mutations seem to be spread across the protein, AHC mutations are located almost exclusively in particular regions of the protein (fi gure 3). The signifi cance of the diff erent mutation patterns in RDP and AHC is currently unknown, but suggests that, unlike in RDP, only specifi c protein disruptions result in AHC. Additionally, rarely the same aminoacid is mutated in RDP and AHC, but even in these cases the aminoacid substitution is disease-specifi c (table 1) . Only one RDP mutation (Asp923Asn) has also been identifi ed in an unusual case of familial AHC. In this multiplex AHC family, four individuals have the Asp923Asn mutation, including one with a diagnosis of AHC and three with some of the defi ning symptoms of AHC (see below). 29 This nearly perfect genotype-phenotype correlation, with a nearly non-overlapping set of mutations associated with AHC or RDP, strongly argues for a distinct functional eff ect of the mutations causing AHC or RDP, which is yet to be elucidated.
Consistent with mutations in ATP1A3 causing neurodevelopmental diseases, only two polymorphic missense mutations (both with low population frequencies [minor allele frequency <0·1%]) have been reported for ATP1A3 (fi gure 2, table 1) in the Exome Variant Server, NHLBI GO Exome Sequencing Project (Seattle, WA, USA). The database houses variants from protein-coding genomes of approximately 6500 individuals who were not identifi ed based on neurodevelopmental or neuropsychiatric disease phenotypes. Evaluating the relationship of the total number of polymorphic functional variants as a function of the total number of variants for each 
Rapid-onset dystonia parkinsonism
Recognition of RDP began in 1993, more than 10 years before ATP1A3 was identifi ed as the causal gene, when Dobyns and colleagues 14 reported a 15-year-old girl who had abrupt onset of dystonia with prominent dysarthria and dysphagia. The disorder was named RDP because of the abrupt onset of dystonic spasms associated with postural instability and bradykinesia that resemble signs of parkinsonism. 13, [38] [39] [40] RDP is also sometimes referred to as dystonia 12 (DYT12; OMIM: 128235). ATP1A3 is the only known RDP gene; however, other RDP genes might exist, as evidenced by one study reporting that, in a select group of 14 patients referred for possible RDP, only three had a mutation in ATP1A3. 19 The clinical presentation of RDP includes three features: its appearance, which often occurs after triggering events such as running, alcohol binges, minor head injuries, overheating, emotional stress, infections, or childbirth; 21 a rapid onset of typically permanent symptoms that develop over hours to days (occasionally even over several weeks); and involuntary movements that are characterised by generalised dystonia with superimposed parkinsonian features (primarily bradykinesia and postural instability without tremor). Many patients present with a rostrocaudal gradient of dystonia and parkinsonism, in the sense that bulbar symptoms are more severe than arm symptoms, and arm symptoms are more severe than leg symptoms. The bulbar and arm symptoms rarely improve after the primary disease onset. A few patients have reported later episodes of abrupt worsening of symptoms that occurred from 1 year to as late as 9 years after the initial onset. One patient, who had transient symptoms after athletic activity, recovered, resumed strenuous athletic activity, and then had permanent onset of fi xed symptoms. Not all patients report a recognised trigger, and a few report antecedent periods of cramping. Patients typically lack other disease features such as diurnal fl uctuation or episodes of symptoms that are typical of patients with AHC.
A recently published cohort of 26 patients with RDP indicated that 76% had onset of motor symptoms by the age of 25 years. 41 In addition to dystonia, patients can also have non-motor manifestations. Recent work suggests that patients with RDP have an increased prevalence of mood disorders (50%) and psychosis (19%) compared with relatives without an ATP1A3 mutation. 41 These fi ndings were observed across families with diff erent ATP1A3 mutations, and are consistent with reports of depression in individuals with ATP1A3 mutations causing motor problems. 16 The originally published diagnostic criteria for RDP require a family history, an onset of the disease in teenage years, and prominent bulbar fi ndings. 19 However, as the number of reported cases of RDP increases, these criteria seem too restrictive for several reasons: more than half of patients with RDP lack a positive family history because the disease is caused by de-novo mutations in small, single-patient families; disease onset has been reported in children and adults; 30 and recognition is growing that there are patients in whom RDP can present with atypical Review features, including second onsets and unusual, mild-tomoderate improvement after the primary onset of disease symptoms (table 2) . Collectively, these fi ndings suggest that the phenotype is broader than originally described in 1993.
Drug therapy in RDP is limited; patients are unresponsive to standard drugs for parkinsonism, including levodopa. 14, 16, 19, 20, 41 Current treatment is limited to benzodiazepines, which have been reported to provide symptomatic relief in some patients.
Alternating hemiplegia of childhood
Although the fi rst report of AHC was by Verret and Steele in 1971, 60 it was not until 1980 that Krageloh and Aicardi 61 fi rst defi ned the syndrome. In 1993, the specifi c clinical criteria to diagnose AHC were proposed. 42 These, named the Aicardi criteria, include seven disease features: (1) paroxysmal episodes of hemiplegia; (2) episodes of bilateral hemiplegia or quadriplegia; (3) other paroxysmal manifestations, such as abnormal eye movements, dystonia, nystagmus, intermittent strabismus, tonic spells, or autonomic disturbance, which can occur during hemiplegia or as isolated events; (4) evidence of permanent neurological dysfunction, which can manifest as intellectual defi ciencies, seizures, ataxia, choreoathetosis, develop mental delay, or persistent motor defi cits such as spastic diplegia or quadriplegia or hypotonia; (5) inducing sleep during a paroxysmal attack might relieve symptoms for a period of time after awakening; (6) fi rst signs of dysfunction occurring before age 18 months; and (7) not being attributed to other disorders. The median age of disease onset of the fi rst paroxysmal event is 3·5 months with a range from the fi rst day of life to 4 years. Developmental delay might not appear until after 12 months. Additional clinical details are summarised in table 2.
Although nearly all cases of AHC are sporadic, some families have an autosomal dominant inheritance of the disorder. [49] [50] [51] 62 In two families a causal ATP1A3 mutation was identifi ed, 29, 31, 62 and in one family a disease-causing ATP1A2 (encoding the α 2 subunit of the Na + /K + -ATPase) mutation was found.
50,51 Consistent with these mutations being highly penetrant, all ATP1A2 or ATP1A3 mutation 31 was later shown to be a rare, inherited mutation, and the disease-causing mutation in this patient was a previously overlooked de-novo Asp801Asn ATP1A3 mutation (unpublished data); thus Asp220Asn is not shown in this table and one additional patient has been counted as having an Asp801Asn mutation. AHC=alternating hemiplegia of childhood. RDP=rapid-onset dystonia parkinsonism. *Compiled from references. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] Review carriers in these families have symptoms of AHC, albeit to varying severity even within families. 29, 31, 50, 51, 62 In addition to these unusual familial cases, other patients have atypical presentations that resemble AHC, although currently a role for ATP1A3 mutation is untested. These include benign nocturnal alternating hemiplegia, which occurs only in boys, 52, 53 mild cases with normal cognitive development, 54 cases in which dystonia is the predominant feature, 54 patients who do not have episodes of quadriplegia, patients who have the fi rst signs of the disorder after the age of 18 months, 54, 55 patients presenting with neonatal seizures, and patients with status epilepticus with associated long-term atrophy on MRI and residual motor and eye movement abnormalities. 56 Over the years, patients with AHC have undergone many treatments to alleviate the frequency and severity of hemiplegia, although success has been very limited. 43, 44 Flunarizine, a calcium channel blocker, performed best because it seemed to reduce the severity and duration of attacks, at least in some patients. [45] [46] [47] [48] Benzodiazepines, which increase the activity of GABA, the major inhibitory neurotransmitter in the CNS, might also have some effi cacy either directly or by inducing sleep, which often relieves attacks.
43,44
Genotype-phenotype correlation
Although the number of patients with AHC or RDP with an identifi ed ATP1A3 mutation is rapidly growing, defi nitive phenotypic patterns have not been found for patients with and without mutations, and in patients with recurring ATP1A3 mutations. 31, 32, 34 However, one small study 63 evaluating the phenotypes of 35 patients with AHC with ATP1A3 mutations reports that patients with the Glu815Lys mutation tend to have earlier onset of symptoms, more severe motor and cognitive disabilities, and more often report status epilepticus and respiratory paralysis compared with patients with AHC with other ATP1A3 mutations. This preliminary fi nding suggests that genotype-phenotype correlations exist and that additional studies will be needed to further evaluate these patterns in larger sample sizes. The ATP1A3 Working Group is currently analysing genotypephenotype correlations in 150 patients.
Biological eff ects of ATP1A3 mutations
In-vitro studies ATP1A3 protein expression and localisation Ten RDP and fi ve AHC ATP1A3 mutations have been investigated at the level of protein expression and cellular localisation of the protein by using heterologous expression systems. 18, 31 These studies revealed that for all except two of the tested RDP mutations the ATP1A3 protein expression was reduced, whereas none of the AHC mutations reduced expression of ATP1A3. RDP mutations were not shown to aff ect the maturation and localisation of the protein in transfected cells;
18 the eff ect of AHC mutations on ATP1A3 localisation has not yet been studied.
ATP1A3 mutations in platelets and fi broblasts
Platelets and fi broblasts from nine patients with AHC have been screened for diff erences in protein expression compared with age-matched and sex-matched controls. 64 A consistent increase in the level of activated lysosomal protein cathepsin B was observed in specimens from patients with AHC, which was shown to increase apoptosis. Although the mechanism remains unclear, 65 in which three cytoplasmic Na + ions are exchanged for two extracellular K + ions for each ATP being hydrolysed, the E 1 conformation preferentially binds Na + , whereas E 2 preferentially binds K + . On the basis of this model, there are several experimental approaches to measure the activity of the Na + /K + -ATPase, and specifi cally the eff ects of diseasecausing mutations in ATP1A3 on the catalytic cycle.
First, using a luminescent kinase assay that measures ADP formed from each catalytic cycle of the Na + /K + -ATPase (fi gure 4) from cells heterologously expressing the wild-type, RDP-causing, or AHC-causing mutant version of the ATP1A3 cDNA, investigators have shown that each mutation reduced the activity of the Na + /K + -ATPase. 31 These fi ndings, coupled with the aforementioned protein expression analyses, suggest that mutations that aff ect Na + /K + -ATPase function, but not the amount of Na + /K + -ATPase per se, seem to result in the more severe AHC phenotype.
Second, since active Na + /K + -ATPase pumps a net charge of +1 out of the cell for each round of the catalytic cycle (fi gure 4), electrophysiology-based approaches can be used to measure, in a living cell or in a patch of excised membrane, the voltage and ion sensitivity of the pump during steady-state activity. Two disease-causing ATP1A3 mutations have been characterised in detail: Asp801Asn and Asp923Asn. The aspartate located at aminoacid position 801 is highly conserved in Na + /K + -ATPases in all investigated species, and is a site that binds either the Na + or K + ions during the catalytic cycle. Expression of the AHC-causing Asp801Asn mutant in Xenopus oocytes showed that the mutation did not generate any measurable pump current, consistent with it being unable to bind K + ions. 67 Analysis of the Asp923Asn mutation, which was identifi ed in both patients with RDP 23, 25, 29, 30 and familial AHC, 29 suggested that protonation at this site was crucial for the movement of Na + and K + across the cell membrane. 68 Third, during the ion transport process, the Na 66,69-71 Because the binding of three Na + ions at the cytoplasmic surface of the ATP1A3 protein is needed to activate the enzyme for phosphorylation from ATP, the affi nity for Na + at these sites can be established by measurement of the Na + dependence of phosphorylation, the affi nity being defi ned by the Na + concentration giving half maximum phosphorylation. So far, RDP-causing mutations Glu277Lys, Thr613Met, Phe780Leu, +Tyr (an extension of the C-terminus with an extra Tyr residue), and the RDPcausing and AHC-causing mutation Asp923Asn have been characterised with these methods. 24, [69] [70] [71] Each of the mutations shows striking reductions of Na + affi nity for activation of phosphorylation. Whereas Na + binding from the cytoplasmic side activates phosphorylation from ATP, binding of K + from the external side triggers dephosphorylation, thereby stimulating ATP hydrolysis. Therefore, the affi nity for external K + can be established by study of the K + dependence of dephosphorylation or ATPase activity at a fi xed Na + concentration. Notably, none of the mutants show a reduced affi nity for K + , indicating a selective disturbance of Na + binding that is associated with mutations causing RDP and one mutation causing AHC (Asp923Asn). 66, [69] [70] [71] The described studies show that a selective reduction of the affi nity of the Na + /K + -ATPase for cytoplasmic Na + without disturbance of K + binding is a central feature in RDP. Consequently, increased intracellular Na + concentration resulting from the reduced Na + affi nity could be a key pathogenic factor in RDP. 66 A rise in intracellular Na + might result in a secondary increase in intracellular Ca² + via the Na + /Ca² + exchange system, which can activate signalling cascades triggered by changes in Ca² + concentration. Additionally, a disturbance of the Na + gradient could aff ect the uptake of neurotransmitters such as dopamine and glutamate. Because several AHC-causing mutations target the same residue (Ile274, Asp801, Asp923) as the one mutated in RDP, an essential question to address is whether Na + affi nity is also typically disturbed in AHC. The affi nity for K + might also be disturbed in AHC, which could also explain why AHC is at the severe end of the phenotypic spectrum, whereas RDP is at the 74 Investigators postulated that a temperaturesensitive gain-of-function mechanism might also underlie the phenotypic consequences of disease-causing mutations in other type II P-type ATPases, including ATP1A3 in AHC and RDP. Although the eff ect of temperature on the functional eff ects of AHC-causing and RDP-causing mutations in Na + /K + -ATPases is unknown, if correct, this mechanism could explain why environmental triggers such as stress, physical exertion, and temperature changes can lead to symptom onset in patients with RDP or AHC (table 2) .
Animal studies Myshkin mice
Several animal models have been used to study the invivo consequences of ATP1A3 modulation (fi gure 5). The aminoacid sequence identity between the human and mouse Na + /K + -ATPase α 3 subunits is about 99%. Heterozygous Myshkin (Atp1a3
Myk/+
; Myk/+) mutant mice have an aminoacid change (Ile810Asn) that aff ects the identical position to Ile810Ser in the human Na + /K + -ATPase α 3 subunit that was identifi ed in a patient with AHC. 31, 75 Molecular modelling of Ile810Asn and Ile810Ser showed that both changes bring about similarly severe structural eff ects on the Na + /K + -ATPase α 3 subunit, including the capacity for effi cient K + movement along the K + access pathway. 73 Ile810Asn was generated through N-nitroso-N-ethylurea (ENU) mutagenesis and results in a normally expressed, but inactive, α 3 protein and a subsequent 36-42% reduction in total Na + /K + -ATPase activity (refl ecting the combined activity of α 1 , α 2 , and α 3 ) in the brain. 75, 81 Heterozygous Myk/+ mice have an unsteady, tremulous gait with occasional splaying of the hindlimbs, but without an overt hemiplegia. 73 Phenotypic analysis revealed a range of other abnormalities in Myk/+ mice, including reduction in body size, motor defi cits in the balance beam and rotarod tests, cognitive defi cits in the fear-conditioning Figure 5 : Na+/K+-ATPase α 3 genetic animal models (A) Atp1α3 mutant mice. The locations of three mutations in the mouse Atp1a3 genomic locus are depicted. Myshkin mice carry a T→A transversion in exon 18 that results in the substitution of asparagine for isoleucine at position 810 (Ile810Asn). 73, 75 Atp1a3 tm1Ling mice carry a point mutation in intron 4 adjacent to the exon-intron splice site that results in aberrant splicing of the gene, adding 126 bp to the RNA transcript. [75] [76] [77] Atp1a3 tm2Kwk mice carry a STOP-polyA cassette that replaces exons 2-6 in Atp1a3. 78 (B) Atpα mutant Drosophila. Atpα CJ10 fruit fl ies carry a G→A transition that results in the substitution of glycine for serine at position 744 (Gly744Ser). 79 Gly744Ser in the Drosophila α subunit is equivalent to mutation Gly755Ser in the human α 3 subunit found in a patient with AHC. 31 (C) atp1a3a/b knockdown zebrafi sh. Knockdown of atp1a3a or atp1a3b RNA transcript by around 65% in 60 hpf embryos had similar phenotypic eff ects. 80 Red stars show point mutations. NKA=Na + K + -ATPase. ↓=lower than wild-type. ↑=greater than wild-type. No change=no change from wild-type. ND=not determined. AHC= alternating hemiplegia of childhood. hpf=hours post-fertilisation. 75, 82 Chronic treatment with rostafuroxin, a compound that antagonises the inhibitory action of ouabain on Na + /K + -ATPase, 83 was also found to reduce the risk-taking behaviour of Myk/+ mice. 81 Eff ects of this intervention on the motor and cognitive defi cits of Myk/+ mice have not yet been established.
Genetic mutation
Gly744Ser
AHC α 3 equivalent
Gly755Ser
NKA α expression
Atp1a3 tm1Ling mice
Heterozygous Atp1a3 tm1Ling/+ mice, which have a point mutation in intron 4 of the Atp1a3 gene, show a reduction of hippocampal α 3 protein expression of around 60% and a reduction of total brain Na + /K + -ATPase activity (of α 1 , α 2 , and α 3 combined) of around 16%. 75, 76, 82 Non-stressed (naive) Atp1a3 tm1Ling/+ mice do not have visible neurological defects or restricted growth, but instead show increased locomotor activity in an open fi eld test and defi cient spatial learning in the Morris water maze test. 76 After exposure to restraint stress for 5 days, female Atp1a3 tm1Ling/+ mice show mild motor defi cits in the balance beam and rotarod tests. 77 Atp1a3 tm1Ling/+ mice exposed to chronic variable stress, consisting of one or two unpredictable mild stressors per day for 6 weeks, have defi cits in total brain Na + /K + -ATPase activity, sociability, and object recognition memory, as well as increased anxiety and depression-like behaviours, compared with non-stressed Atp1a3 tm1Ling/+ mice. 82 In Atp1a3 wild-type mice, chronic variable stress also led to depression-like behaviour and reduced sociability, but had no eff ect on Na + /K + -ATPase activity, anxiety, or object recognition memory compared with non-stressed wild-type controls. 82 
Homozygous
Atp1a3
tm1Ling pups die shortly after birth. Perfusion of the Na + /K + -ATPase inhibitor ouabain into the cerebellum and basal ganglia was found to induce mild dyskinesia in wild-type C57BL/6 mice. 85 When mice were subsequently exposed for 2 h to stress provided in the form of random electric foot shocks in a warm environment (38°C), 70% of the mice developed persistent dystonia and rigidity. 85 These mice show hallmark symptoms of RDP, including dystonia and parkinsonism induced by stress. However, this approach is limited by the similar affi nities of the α 2 and α 3 isoforms for ouabain, 86 thus precluding α 3 specifi city in this animal model.
Zebrafi sh
Zebrafi sh (Danio rerio) have two ATP1A3 orthologues, atp1a3a and atp1a3b. 87 The paralogous α 3a and α 3b subunits have aminoacid identities of 95% with each other and 91-92% with the human Na + /K + -ATPase α 3 subunit protein sequence. Consistent with mammalian Na + /K + -ATPase α 3 subunit protein expression, the transcripts of atp1a3a and atp1a3b are primarily expressed in the brain, albeit with distinct expression profi les. In 60 h postfertilisation zebrafi sh embryos, the atp1a3a transcript is widely distributed throughout the brain, whereas distribution of atp1a3b mRNA is localised to particular brain structures. Despite having distinct expression profi les, targeted knockdown of atp1a3a or atp1a3b by morpholino antisense oligonucleotides results in severe brain ventricle dilation in 60 h post-fertilisation embryos, suggesting that both α 3 paralogues are needed for brain ventricle maintenance. The extent of brain ventricle dilation was reduced by co-injection of the mRNA of the knocked-down gene, but atp1a3b mRNA did not crossrescue the phenotype of atp1a3a-knockdown embryos. Similarly, atp1a3a mRNA did not cross-rescue the phenotype of atp1a3b-knockdown embryos. Both morphants display abnormal spontaneous motility and an abnormal response to tactile stimulation with a needle, 80 suggesting that both α 3 paralogues are needed for embryonic motility.
Drosophila
The gene Atpα (FlyBase ID: FBgn0002921) in Drosophila melanogaster fruit fl ies encodes the α subunit of the Na + /K + -ATPase, which is orthologous to all vertebrate α subunits, and has aminoacid sequence identities of 76-77% with the α 1 , α 2 , and α 3 subunits of human beings. 88 Although the Drosophila Atpα gene is not a specifi c orthologue of ATP1A3, eight missense mutations, generated through ethylmethanesulfonate mutagenesis at highly conserved aminoacid residues, lead to AHCrelevant phenotypic abnormalities in adult heterozygous fl ies. 79, 89 Flies from any of six lines with mutations (Ser201Leu, Pro262Leu, Ser348Thr, Gly528Ser, Ala588Thr, Gly744Ser) in Atpα that were repeatedly knocked to the bottom of a vial using a standard laboratory vortexer showed transient mechanical stress-induced paralysis. 79 Two other mutant lines (Asp981Asn, Glu928Lys) did not show this phenotype when maintained at an ambient temperature of 20-22°C, but showed temperaturesensitive mechanical stress-induced paralysis when maintained at 28°C. 89 When exposed to a temperature of 37-38°C, three mutant lines (Gly744Ser, Asp981Asn, Glu928Lys) showed temperature-sensitive paralysis that was reversed when the ambient temperature was lowered to 20-22°C. 79, 89 When the bodyweight of male fl ies of six of the same mutant lines was measured, only Ser201Leu mutant fl ies showed a reduction compared with wild-type fl ies. 79 Western blotting of homogenised fl y heads showed that the expression of Na + /K + -ATPase α subunit was reduced in two of the Atpα mutants (Ser348Thr, Ala588Thr), but unchanged in the other four mutants. 79 Mutations Gly744Ser and Asp981Asn in the Drosophila α subunit, which led to temperature-sensitive paralysis, aff ect equivalent aminoacid residues in the human Na + /K + -ATPase α 3 subunit, namely mutations Gly755Cys, Gly755Ser, and Asp992Tyr, which were identifi ed in patients with AHC (table 3) . 31, 32 All eight missense mutations are homozygous lethal.
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Conclusions
Since the original descriptions of RDP and AHC, substantial work has been done to characterise their clinical presentation and pathophysiology. Through the identifi cation of disease-causing mutations in ATP1A3, these two seemingly unrelated diseases are now linked, allowing new opportunities to obtain insight into their biological bases.
We now understand that protein-modifying genetic variations in ATP1A3 rarely occur in the general population and, when they do, the risk of severe neurological disease is very high. This understanding has led to a new research area, investigating which other diseases might be associated with mutations in ATP1A3. One could postulate that ATP1A3 mutations might also be found in patients with seizures, psychiatric conditions, or other less severe types of dystonia or ataxia. As next-generation sequencing becomes widely used in day-to-day clinical practice, the role of ATP1A3 mutations in a wider range of phenotypes might become apparent. However, as this genotypephenotype spectrum is being defi ned, we can already begin cataloguing ATP1A3 disease-specifi c mutations and polymorphic protein-disrupting variants in the general population, to establish molecular and physiological changes associated with these DNA variations in in-vitro and in-vivo test paradigms like those described in this Review. Data from these studies can be used to develop better research models with tiered complexity. We envisage that these studies will include establishing disease models at the transporter level in individual cells, multicellular network models using induced pluripotent cells diff erentiated into neurons, ex-vivo studies in brain slices to study tissue-level eff ects, and, fi nally, evaluations at the organism level to assess in-vivo consequences in animal models. With these model systems we can begin to relate molecular changes to the phenotypic presentations associated with these disorders, including the episodic nature of AHC, how particular stimuli lead to the onset of symptoms, the age-dependent onset of RDP, and the variable eff ects on organ systems and brain structures that probably underlie the diverse phenotypic presentations. 
Search strategy and selection criteria
References cited in this Review were identifi ed through PubMed searches using the search terms "ATP1A3", "alternating hemiplegia of childhood", "rapid-onset dystonia parkinsonism", and "Na,K-ATPase ", from December, 1993, until January, 2014. Articles were identifi ed through searches of the reference lists of the articles found with the above cited search terms and of the authors' own fi les. All references used in this Review were published in English, and were selected according to originality and relevance to the content of this Review.
Review
Importantly, once key biomarkers of disease pathophysiology are identifi ed, we will be able to screen for compounds to rectify the pathophysiological changes associated with ATP1A3 mutations. In summary, genetics has illuminated key aspects of disease pathophysiology for both AHC and RDP. Although extensive work is needed to disentangle the complex biology underlying these disorders, we are poised with evolving research approaches to rapidly translate these genetic discoveries to detailed disease pathophysiology, to improve understanding of developmentally mediated and environmentally triggered disease presentation, and ultimately to develop treatments for these debilitating diseases.
